TEVA - Teva Pharmaceutical Industries Limited Stock Price, News & Analysis

$13.70 0.22 (1.63 %)
(As of 11/24/2017 01:37 PM ET)
Previous Close$13.48
Today's Range$14.28 - $13.56
52-Week Range$10.85 - $38.49
Volume15.86 million shs
Average Volume15.44 million shs
Market Capitalization$13.70 billion
P/E Ratio3.11
Dividend Yield7.05%
Beta0.52

About Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries Limited logoTeva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.


Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TEVA
CUSIPN/A

Debt

Debt-to-Equity Ratio1.20%
Current Ratio0.96%
Quick Ratio0.66%

Price-To-Earnings

Trailing P/E Ratio3.11
Forward P/E Ratio3.61
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.90 billion
Price / Sales0.64
Cash Flow$6.68 per share
Price / Cash2.05
Book Value$26.25 per share
Price / Book0.52

Dividend

Annual Dividend$0.94
Dividend Yield7.1%

Profitability

Trailing EPS($5.95)
Net Income$329 million
Net Margins-24.35%
Return on Equity15.70%
Return on Assets5.12%

Miscellaneous

Employees56,960
Outstanding Shares1,016,000,000

Frequently Asked Questions for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What is Teva Pharmaceutical Industries Limited's stock symbol?

Teva Pharmaceutical Industries Limited trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries Limited pay dividends? What is the dividend yield for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited declared a quarterly dividend on Thursday, November 2nd. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 annualized dividend and a dividend yield of 2.48%. The ex-dividend date of this dividend is Monday, November 27th. View Teva Pharmaceutical Industries Limited's Dividend History.

How were Teva Pharmaceutical Industries Limited's earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its earnings results on Thursday, May, 11th. The company reported $1.06 EPS for the quarter, meeting the Zacks' consensus estimate of $1.06. The business had revenue of $5.63 billion for the quarter, compared to analyst estimates of $5.69 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.70% and a negative net margin of 24.35%. Teva Pharmaceutical Industries Limited's revenue for the quarter was up 17.0% on a year-over-year basis. During the same period last year, the business posted $1.20 EPS. View Teva Pharmaceutical Industries Limited's Earnings History.

When will Teva Pharmaceutical Industries Limited make its next earnings announcement?

Teva Pharmaceutical Industries Limited is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Teva Pharmaceutical Industries Limited.

What guidance has Teva Pharmaceutical Industries Limited issued on next quarter's earnings?

Teva Pharmaceutical Industries Limited updated its fourth quarter earnings guidance on Thursday, November, 2nd. The company provided earnings per share guidance of $0.70-0.80 for the period, compared to the Thomson Reuters consensus estimate of $1.06. The company issued revenue guidance of $5.3-5.4 billion, compared to the consensus revenue estimate of $5.68 billion.

Where is Teva Pharmaceutical Industries Limited's stock going? Where will Teva Pharmaceutical Industries Limited's stock price be in 2017?

26 brokers have issued 1-year price objectives for Teva Pharmaceutical Industries Limited's stock. Their forecasts range from $7.00 to $80.00. On average, they anticipate Teva Pharmaceutical Industries Limited's stock price to reach $21.47 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries Limited.

What are Wall Street analysts saying about Teva Pharmaceutical Industries Limited stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries Limited stock:

  • 1. Cantor Fitzgerald analysts commented, "Today Mylan (MYL; Neutral) announced the UK High Court of Justice found all claims of Teva’s patent EP ‘355 relating to Copaxone 40mg/mL invalid based on obviousness." (10/26/2017)
  • 2. Maxim Group analysts commented, "Shares of TEVA are under pressure in the wake of the FDA’s approval of Mylan’s ANDA for generic copaxone 3x/week & 20 mg/ml QD injection. Teva has a press release estimating the impact of the two launches to its 4Q earnings of at least $0.25. Our estimates are under review but our Hold remaining remains in-effect. We had anticipated generic copaxone (3x) but not until 2018." (10/4/2017)
  • 3. According to Zacks Investment Research, "Pricing erosion in the U.S. generics business and the continued deterioration in Venezuela is hurting sales at Teva which led to a guidance and dividend cut in August. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products and a high cost base and debt load. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to growth of the Generics unit. Meanwhile, Teva is focusing on cost cutting and divestments to boost growth. However, a clear path to growth is not visible. Estimates have declined ahead of the company’s Q3 earnings release. The company also has a negative record of earnings surprises in recent quarters." (10/4/2017)
  • 4. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)
  • 5. Royal Bank Of Canada analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)

Are investors shorting Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited saw a increase in short interest in October. As of October 31st, there was short interest totalling 67,929,666 shares, an increase of 0.5% from the October 13th total of 68,239,599 shares. Based on an average trading volume of 18,798,714 shares, the days-to-cover ratio is presently 3.6 days.

Who are some of Teva Pharmaceutical Industries Limited's key competitors?

Who are Teva Pharmaceutical Industries Limited's key executives?

Teva Pharmaceutical Industries Limited's management team includes the folowing people:

  • Sol J. Barer Ph.D., Chairman of the Board (Age 69)
  • Kaare Schultz, President, Chief Executive Officer (Age 56)
  • Eyal Desheh, Group Executive Vice President, Chief Financial Officer (Age 65)
  • Dipankar Bhattacharjee, President and Chief Executive Officer-Global Generic Medicines Group (Age 56)
  • Carlo de Notaristefani, President and Chief Executive Officer-Global Operations (Age 59)
  • Robert Koremans, President & Chief Executive Officer-Global Specialty Medicines (Age 55)
  • Iris Beck-Codner, Group Executive Vice President - Corporate Marketing & Communication (Age 51)
  • Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D (Age 55)
  • Mark Sabag, Group Executive Vice President-Human Resources (Age 46)
  • David M. Stark, Group Executive Vice President-Chief Legal Officer (Age 48)

Who owns Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.47%), Schroder Investment Management Group (0.61%), Migdal Insurance & Financial Holdings Ltd. (0.59%), Macquarie Group Ltd. (0.43%), Clal Insurance Enterprises Holdings Ltd (0.30%) and Menora Mivtachim Holdings LTD. (0.27%). View Institutional Ownership Trends for Teva Pharmaceutical Industries Limited.

Who sold Teva Pharmaceutical Industries Limited stock? Who is selling Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock was sold by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Palisade Capital Management LLC NJ, Bank of New York Mellon Corp, Thornburg Investment Management Inc., Zurcher Kantonalbank Zurich Cantonalbank, Janus Henderson Group PLC, Brown Advisory Inc. and Pictet Asset Management Ltd.. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.

Who bought Teva Pharmaceutical Industries Limited stock? Who is buying Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Menora Mivtachim Holdings LTD., Mackenzie Financial Corp, Schroder Investment Management Group, Harel Insurance Investments & Financial Services Ltd., Psagot Investment House Ltd., Commerzbank Aktiengesellschaft FI and Van ECK Associates Corp. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.

How do I buy Teva Pharmaceutical Industries Limited stock?

Shares of Teva Pharmaceutical Industries Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries Limited's stock price today?

One share of Teva Pharmaceutical Industries Limited stock can currently be purchased for approximately $13.69.

How big of a company is Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited has a market capitalization of $13.70 billion and generates $21.90 billion in revenue each year. The company earns $329 million in net income (profit) each year or ($5.95) on an earnings per share basis. Teva Pharmaceutical Industries Limited employs 56,960 workers across the globe.

How can I contact Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited's mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]


MarketBeat Community Rating for Teva Pharmaceutical Industries Limited (TEVA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  892 (Vote Outperform)
Underperform Votes:  722 (Vote Underperform)
Total Votes:  1,614
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Sell Ratings, 15 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.04)
Consensus Price Target: $21.47 (56.71% upside)

Consensus Price Target History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Price Target History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Analysts' Ratings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017MizuhoReiterated RatingNeutral -> Neutral$15.00 -> $12.00N/AView Rating Details
11/14/2017Cantor FitzgeraldSet Price TargetHold$10.00N/AView Rating Details
11/12/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
11/13/2017J P Morgan Chase & CoDowngradeNeutral -> Underweight$11.48 -> $11.00N/AView Rating Details
11/6/2017Susquehanna Bancshares IncLower Price TargetPositive -> Positive$20.00 -> $14.00N/AView Rating Details
11/6/2017Credit Suisse GroupReiterated RatingUnderperform$14.00 -> $8.00N/AView Rating Details
11/5/2017Royal Bank Of CanadaBoost Price TargetUnderperform$8.00 -> $13.00N/AView Rating Details
11/3/2017Piper Jaffray CompaniesReiterated RatingHold$12.00N/AView Rating Details
11/3/2017Morgan StanleyLower Price TargetUnderweight$14.00 -> $7.00N/AView Rating Details
11/3/2017Deutsche Bank AGDowngradeBuy -> Hold$14.00N/AView Rating Details
11/2/2017Wells Fargo & CompanyDowngradeMarket Perform$17.00 -> $11.36N/AView Rating Details
10/25/2017Evercore ISISet Price TargetBuy$38.00N/AView Rating Details
10/20/2017Barclays PLCSet Price TargetHold$21.00 -> $19.00N/AView Rating Details
10/4/2017Cowen IncReiterated RatingMarket Perform$30.00 -> $18.00N/AView Rating Details
10/4/2017Maxim GroupReiterated RatingHoldN/AView Rating Details
10/4/2017BTIG ResearchReiterated RatingBuy$24.00MediumView Rating Details
9/21/2017Sanford C. BernsteinLower Price TargetMkt Perform -> Market Perform$28.00 -> $20.00LowView Rating Details
9/13/2017GabelliReiterated RatingBuyLowView Rating Details
9/12/2017Jefferies Group LLCLower Price TargetHold$21.00 -> $18.50HighView Rating Details
9/6/2017JMP SecuritiesBoost Price TargetUnderperform$13.00 -> $14.00LowView Rating Details
8/31/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$28.00 -> $21.00LowView Rating Details
8/16/2017Citigroup Inc.DowngradeBuy -> Neutral$32.00 -> $19.00MediumView Rating Details
8/3/2017CIBCReiterated RatingOutperform -> Market PerformHighView Rating Details
2/28/2017ArgusDowngradeBuy -> Hold$59.35 -> $31.90N/AView Rating Details
1/31/2017Bank of America CorporationUpgradeNeutral -> BuyN/AView Rating Details
12/23/2016GuggenheimReiterated RatingBuy$80.00N/AView Rating Details
10/7/2016Leerink SwannSet Price TargetBuy$57.00N/AView Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveN/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00N/AView Rating Details
11/27/2015Berenberg BankLower Price TargetHold$72.00 -> $65.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Earnings by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Earnings History by Quarter for Teva Pharmaceutical Industries Limited (NYSE TEVA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018        
8/3/20176/30/2017$1.06$0.99$5.72 billion$5.69 billionViewListenView Earnings Details
5/11/2017Q1 17$1.06$1.06$5.69 billion$5.63 billionViewN/AView Earnings Details
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.71 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Current Year EPS Consensus Estimate: $3.8 EPS
Next Year EPS Consensus Estimate: $2.84 EPS

Dividends

Current Dividend Information for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Next Dividend:12/12/2017
Annual Dividend:$0.94
Dividend Yield:6.86%
Dividend Growth:2.10% (3 Year Average)
Payout Ratio:-15.80% (Trailing 12 Months of Earnings)
24.74% (Based on This Year's Estimates)
33.10% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dividend History by Quarter for Teva Pharmaceutical Industries Limited (NYSE TEVA)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/2/2017quarterly$0.092.74%11/27/201711/28/201712/12/2017
8/7/2017quarterly$0.091.83%8/25/20178/29/20179/14/2017
5/11/2017quarterly$0.344.28%6/1/20176/5/20176/22/2017
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries Limited (NYSE TEVA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Teva Pharmaceutical Industries Limited (NYSE TEVA)

Source:
DateHeadline
Struggling Teva Announces Mass Layoffs - Seeking AlphaStruggling Teva Announces Mass Layoffs - Seeking Alpha
seekingalpha.com - November 24 at 9:53 AM
Teva on Women’s Health—And Other Recent DevelopmentsTeva on Women’s Health—And Other Recent Developments
finance.yahoo.com - November 24 at 9:53 AM
How Teva’s Respiratory and Oncology Portfolios Are Positioned after 3Q17How Teva’s Respiratory and Oncology Portfolios Are Positioned after 3Q17
finance.yahoo.com - November 24 at 9:53 AM
Morning Movers: Digging In the Haystack for Teva, NektarMorning Movers: Digging In the Haystack for Teva, Nektar
finance.yahoo.com - November 24 at 9:53 AM
Teva Spikes in Pre-Market Amid Reports of Significant U.S. Job CutsTeva Spikes in Pre-Market Amid Reports of Significant U.S. Job Cuts
finance.yahoo.com - November 24 at 9:53 AM
Why Teva Will Be Hard Pressed to Maintain Its Dividend in the Long TermWhy Teva Will Be Hard Pressed to Maintain Its Dividend in the Long Term
finance.yahoo.com - November 23 at 5:01 PM
Inside Teva’s 3Q17 PerformanceInside Teva’s 3Q17 Performance
finance.yahoo.com - November 23 at 5:01 PM
Massive layoffs coming to Teva - Seeking AlphaMassive layoffs coming to Teva - Seeking Alpha
seekingalpha.com - November 23 at 5:01 PM
Teva Pharmaceutical: Generidiculous! - Seeking AlphaTeva Pharmaceutical: Generidiculous! - Seeking Alpha
seekingalpha.com - November 22 at 9:46 AM
Teva Pharmaceutical Industries Limited 2017 Q3 - Results - Earnings Call SlidesTeva Pharmaceutical Industries Limited 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 21 at 11:35 AM
Teva Pharmaceutical Industries Limited (TEVA) Given Consensus Recommendation of "Hold" by BrokeragesTeva Pharmaceutical Industries Limited (TEVA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 20 at 3:48 PM
Zacks: Analysts Anticipate Teva Pharmaceutical Industries Limited (TEVA) Will Post Quarterly Sales of $5.33 BillionZacks: Analysts Anticipate Teva Pharmaceutical Industries Limited (TEVA) Will Post Quarterly Sales of $5.33 Billion
www.americanbankingnews.com - November 20 at 2:24 PM
Why Fitch Sacked Teva - Seeking AlphaWhy Fitch Sacked Teva - Seeking Alpha
seekingalpha.com - November 20 at 11:00 AM
Teva Pharmaceutical Industries Limited (TEVA) Earns Neutral Rating from MizuhoTeva Pharmaceutical Industries Limited (TEVA) Earns Neutral Rating from Mizuho
www.americanbankingnews.com - November 18 at 11:38 AM
Health and Happiness (H&H) Intl. Hldgs. Ltd. -- Moodys: Health and Happiness ratings unaffected by Swisses buy-back of distribution rightsHealth and Happiness (H&H) Int'l. Hldgs. Ltd. -- Moody's: Health and Happiness' ratings unaffected by Swisse's buy-back of distribution rights
finance.yahoo.com - November 18 at 9:16 AM
Teva Pharmaceutical Industries Limited (TEVA) Is Trading At A 48.87% Discount To Its Intrinsic ValueTeva Pharmaceutical Industries Limited (TEVA) Is Trading At A 48.87% Discount To Its Intrinsic Value
finance.yahoo.com - November 18 at 9:16 AM
ETFs with exposure to Teva Pharmaceutical Industries Ltd. : November 17, 2017ETFs with exposure to Teva Pharmaceutical Industries Ltd. : November 17, 2017
finance.yahoo.com - November 18 at 9:16 AM
What We Can Learn From Tevas Q3 Report - Seeking AlphaWhat We Can Learn From Teva's Q3 Report - Seeking Alpha
seekingalpha.com - November 18 at 9:16 AM
Teva Pharmaceutical Industries Limited (TEVA) Expected to Announce Earnings of $0.86 Per ShareTeva Pharmaceutical Industries Limited (TEVA) Expected to Announce Earnings of $0.86 Per Share
www.americanbankingnews.com - November 18 at 9:14 AM
Exploring Antares Pharma’s Current Pipeline of ProductsExploring Antares Pharma’s Current Pipeline of Products
finance.yahoo.com - November 16 at 9:16 AM
Teva Announces Prescription Copay Savings Program for Generic Gleevec - Business Wire (press release)Teva Announces Prescription Copay Savings Program for Generic Gleevec - Business Wire (press release)
www.businesswire.com - November 15 at 2:28 PM
Oppenheimer Discouraged on Teva’s Ability to Generate Gains in the Short-TermOppenheimer Discouraged on Teva’s Ability to Generate Gains in the Short-Term
finance.yahoo.com - November 15 at 2:28 PM
Behind Sanofi’s 3Q17 Revenue GrowthBehind Sanofi’s 3Q17 Revenue Growth
finance.yahoo.com - November 15 at 2:28 PM
Behind Novartis’s Respiratory Drug Performance in 3Q17Behind Novartis’s Respiratory Drug Performance in 3Q17
finance.yahoo.com - November 15 at 2:28 PM
Cantor Continues to Play It Cautious on Teva Following Management MeetingCantor Continues to Play It Cautious on Teva Following Management Meeting
finance.yahoo.com - November 15 at 2:28 PM
[$$] Foundation Consumer Healthcare Buys Plan B One-Step From Teva[$$] Foundation Consumer Healthcare Buys Plan B One-Step From Teva
finance.yahoo.com - November 15 at 2:28 PM
GE among IQ100 leadersGE among IQ100 leaders
finance.yahoo.com - November 15 at 2:28 PM
Teva Announces Prescription Copay Savings Program for Generic Gleevec® Tablets in the United StatesTeva Announces Prescription Copay Savings Program for Generic Gleevec® Tablets in the United States
finance.yahoo.com - November 15 at 2:28 PM
Teva Pharmaceutical Industries Limited (TEVA) Given a $10.00 Price Target by Cantor Fitzgerald AnalystsTeva Pharmaceutical Industries Limited (TEVA) Given a $10.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - November 14 at 9:52 PM
Tel Aviv District Court Ordered MediWound to Purchase Approximately $1.5 Million of PolyHeal Shares; MediWound ... - GlobeNewswire (press release)Tel Aviv District Court Ordered MediWound to Purchase Approximately $1.5 Million of PolyHeal Shares; MediWound ... - GlobeNewswire (press release)
globenewswire.com - November 14 at 9:23 AM
Teva: Its Never Too Late to SellTeva: It's Never Too Late to Sell
finance.yahoo.com - November 14 at 9:23 AM
For Teva Pharmaceuticals, No Recovery In Sight, Says AnalystFor Teva Pharmaceuticals, No Recovery In Sight, Says Analyst
finance.yahoo.com - November 14 at 9:23 AM
Today’s Research Reports on Trending Tickers: Teva Pharmaceutical and TransoceanToday’s Research Reports on Trending Tickers: Teva Pharmaceutical and Transocean
finance.yahoo.com - November 14 at 9:23 AM
Triton (European Loan Conduit No. 26) PLC (ELoC 26) -- Moodys assigns B2 CFR to IWH UK Finco LimitedTriton (European Loan Conduit No. 26) PLC (ELoC 26) -- Moody's assigns B2 CFR to IWH UK Finco Limited
finance.yahoo.com - November 14 at 9:23 AM
Teva Pharmaceutical Industries Limiteds (TEVA) Hold Rating Reiterated at Oppenheimer Holdings, Inc.Teva Pharmaceutical Industries Limited's (TEVA) Hold Rating Reiterated at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 13 at 2:29 PM
Sphera Funds Management Ltd. Buys Cellcom Israel, Allergan PLC, Teva Pharmaceutical Industries, ... - NasdaqSphera Funds Management Ltd. Buys Cellcom Israel, Allergan PLC, Teva Pharmaceutical Industries, ... - Nasdaq
www.nasdaq.com - November 12 at 12:36 AM
Short Sellers Back Way Off Major PharmaShort Sellers Back Way Off Major Pharma
finance.yahoo.com - November 11 at 2:29 PM
Teva Pharmaceutical Industries Ltd. :TEVA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017Teva Pharmaceutical Industries Ltd. :TEVA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017
finance.yahoo.com - November 10 at 10:27 AM
Teva Pharma: Junk Rating Adds to WoesTeva Pharma: Junk Rating Adds to Woes
finance.yahoo.com - November 9 at 7:41 PM
Wall Street Is All Mixed Up About Teva Pharmaceutical; Jami Rubin Cuts Price TargetWall Street Is All Mixed Up About Teva Pharmaceutical; Jami Rubin Cuts Price Target
finance.yahoo.com - November 9 at 7:41 PM
Why Teva Pharma Could Fall Another 50%Why Teva Pharma Could Fall Another 50%
finance.yahoo.com - November 9 at 7:41 PM
Teva: Stop Tucking These Away - Seeking AlphaTeva: Stop 'Tucking These Away' - Seeking Alpha
seekingalpha.com - November 9 at 2:39 PM
Teva Pharmaceutical Is Getting a Beating Between Analysts and Credit Rating Agencies Who See Valuation Heading Down the DrainTeva Pharmaceutical Is Getting a Beating Between Analysts and Credit Rating Agencies Who See Valuation Heading Down the Drain
finance.yahoo.com - November 9 at 2:39 PM
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares DownVIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
finance.yahoo.com - November 9 at 2:39 PM
Teva Will Sink 50% After Fitch Downgrade: HSBCTeva Will Sink 50% After Fitch Downgrade: HSBC
finance.yahoo.com - November 9 at 2:39 PM
Active Biotech AB - Interim report January - September 2017Active Biotech AB - Interim report January - September 2017
feeds.benzinga.com - November 9 at 3:26 AM
Teva Pharmaceutical Could Settle At $10 - Seeking AlphaTeva Pharmaceutical Could Settle At $10 - Seeking Alpha
seekingalpha.com - November 7 at 11:53 AM
Tuesdays Vital Data: Alibaba Group Holding Ltd (BABA), Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and ... - Investorplace.comTuesday's Vital Data: Alibaba Group Holding Ltd (BABA), Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and ... - Investorplace.com
investorplace.com - November 7 at 11:53 AM
Teva: What To Do? - Seeking AlphaTeva: What To Do? - Seeking Alpha
seekingalpha.com - November 7 at 11:53 AM
Teva Pharmaceutical Industries Limited (TEVA) Downgraded by HSBC Holdings plc to ReduceTeva Pharmaceutical Industries Limited (TEVA) Downgraded by HSBC Holdings plc to Reduce
www.americanbankingnews.com - November 7 at 8:33 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Teva Pharmaceutical Industries Limited (NYSE TEVA) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.